PharmaCyte Biotech, Inc. (PMCB)

Name: PharmaCyte Biotech, Inc. (PMCB) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001157075 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated NV
Fiscal year ends Apr 30

For the year ended 2026-04-30, PharmaCyte Biotech, Inc. reported revenue of $0. Over the twelve months to 2026-07-31, revenue was $0.

Key ratios (year ended 2026-04-30)

-58.3%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-07-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-07-31	2026-04-30	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30	2020-04-30	2019-04-30	2018-04-30	2017-04-30
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expense	$356.1K	$391.3K	$438.4K	$407.4K	$468.5K	$690.9K	$916.2K	$301.2K	$460.1K	$2.00M	$1.18M
Operating Income	-$7.01M	-$6.85M	-$4.38M	-$8.52M	-$6.46M	-$4.39M	-$3.62M	-$3.83M	-$4.10M	-$6.98M	-$4.44M
Net Income	-$16.15M	-$19.42M	$30.66M	$333.8K	-$4.32M	-$4.24M	-$3.55M	-$3.83M	-$4.07M	-$6.83M	-$4.44M
EPS (Diluted)	n/a	-$2.77	$3.19	-$1.80	-$0.22	-$0.27	-$2.45	n/a	n/a	n/a	n/a
Total Assets	$36.71M	$46.75M	$55.17M	$59.90M	$73.28M	$90.62M	$7.40M	$6.17M	$5.78M	$6.41M	$8.67M
Total Liabilities	$6.90M	$11.77M	$3.28M	$20.39M	$586.6K	$704.4K	$724.8K	$1.08M	$742.9K	$644.2K	$580.2K
Shareholders' Equity	$27.51M	$33.29M	$51.89M	$27.65M	$72.69M	$89.92M	$6.68M	$5.09M	$5.04M	$5.77M	$8.09M
Cash & Equivalents	$17.74M	$18.60M	$15.17M	$50.18M	$68.04M	$85.40M	n/a	n/a	n/a	n/a	n/a
Operating Cash Flow	-$3.94M	-$5.15M	-$2.98M	-$2.15M	-$3.79M	-$4.12M	-$3.33M	-$2.34M	-$2.88M	-$5.08M	-$3.34M
Share Repurchases	n/a	$401.6K	$2.54M	$28.20M	$13.56M	$0	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	10.74M	10.74M	6.80M	8.04M	16.79M	20.72M	1.59M	1.09M	1.19B	1.01B	905.35M
Weighted Average Diluted Shares	n/a	8.38M	7.33M	9.58M	19.49M	15.52M	1.45M	903.8K	1.10B	968.64M	845.31M
EPS (Basic)	n/a	-$2.77	$3.19	-$1.80	-$0.22	-$0.27	-$2.45	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView